沐舒坦雾化吸入治疗婴幼儿支气管肺炎疗效的Meta分析

A meta-analysis on inhalation of Mucosolvan in the treatment of bronchopneumonia in infants

目的:系统评价沐舒坦雾化吸入治疗婴幼儿支气管肺炎的效果。方法:通过多种途径检索2003年1月1日至2009年12月1日应用沐舒坦雾化吸入治疗婴幼儿支气管肺炎的随机对照研究或半随机对照研究文献,然后进行Meta分析。结果:纳入的9项研究Meta分析结果显示,沐舒坦雾化吸入治疗组总有效率明显高于对照组(OR=3.45,95%CI:2.30~5.17,P<0.000 01);沐舒坦雾化吸入能显著缩短咳嗽持续时间(WMD=-0.95,95%CI:-1.12^-0.78,P<0.000 01),能显著缩短肺部啰音消失时间(WMD=-0.89,95%CI:-1.17^-0.62,P<0.000 01),能显著缩短患儿住院时间(WMD=-0.91,95%CI:-1.20^-0.61,P<0.000 01)。结论:沐舒坦雾化吸入治疗婴幼儿支气管肺炎具有较好的疗效,但纳入的临床研究质量普遍较低,仍需更多严格的、多中心的随机双盲对照研究,以提供更有说服力的证据。

Objective： To explore the safety and efficacy of inhalation of Mucosolvan in the treatment of bronchopneumonia in infants.Methods： The randomized,quasi-randomized control clinical trials regarding the safety and efficacy of inhalation of Mucosolvan in the treatment of bronchopneumonia in infants were quantitatively evaluated using meta-analysis.Results： Nine articles were included.Inhalation of Mucosolvan had a better efficacy compared with those who were not（OR=3.45,95%CI： 2.30-5.17,P 0.000 01）.Inhalation of Mucosolvan reduced the duration of the cough,pulmonary rales,hospital stay（P0.05）.Conclusion： Inhalation of Mucosolvan is safe and effective in treating bronchopneumonia in infants.Because of the poor quality of reporting the included trials,further multicentre and large-scale RCTs are still needed to be performed to evaluate the potential benefit of inhalation of Mucosolvan in the treatment of bronchopneumonia in infants.